Proactive strategies for regorafenib in metastatic colorectal cancer: Implications for optimal patient management

Cancer Management and Research

Volumn 6, Issue 1, 2014, Pages 93-103

  Khan, Gazala ^a   Moss, Rebecca A ^b   Braiteh, Fadi ^c,d   Saltzman, Marc ^e  

^a HENRY FORD HOSPITAL   (United States)

^b RUTGERS UNIVERSITY   (United States)

^c Developmental Therapeutics Committee and Co Chair of the Genitourinary Committee   (United States)

^d Department of Hematology Oncology   (United States)

^e Innovative Medical Research of South Florida Inc   (United States)

Author keywords

Adverse event management; CORRECT trial; Multikinase inhibitor

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; DIHYDROPYRIDINE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; FLUOROURACIL; FOLINIC ACID; IRINOTECAN; LOPERAMIDE; OCTREOTIDE; OPIATE; OXALIPLATIN; PLACEBO; REGORAFENIB; THIAZIDE DIURETIC AGENT;

ASTHENIA; BLEEDING; COMORBIDITY; DECREASED APPETITE; DIARRHEA; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG ERUPTION; DRUG MECHANISM; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSPHONIA; ERYTHEMA; FATIGUE; FEVER; GENERALIZED RASH; HAND FOOT SKIN REACTION; HAND FOOT SYNDROME; HEADACHE; HUMAN; HYPERBILIRUBINEMIA; HYPERTENSION; HYPOPHOSPHATEMIA; INFECTION; LIVER DYSFUNCTION; LIVER FUNCTION TEST; MACULAR RASH; MACULOPAPULAR RASH; METASTATIC COLORECTAL CANCER; MUCOSA INFLAMMATION; MULTIPLE CYCLE TREATMENT; OVERALL SURVIVAL; PAIN; PAPULAR RASH; PATIENT CARE; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PROGRESSION FREE SURVIVAL; PRURITUS; RANDOMIZED CONTROLLED TRIAL (TOPIC); RASH; RECOMMENDED DRUG DOSE; REVIEW; SKIN DISEASE; TREATMENT OUTCOME; UNSPECIFIED SIDE EFFECT;

EID: 84895763109     PISSN: None     EISSN: 11791322     Source Type: Book Series    
DOI: 10.2147/CMAR.S52217     Document Type: Review

References (37)

1. Fearon ER. Molecular genetics of colorectal cancer. Annu Rev Pathol. 2011;6:479-507.
2. Cancer Genome Atlas Network. Comprehensive molecular characterization of human colon and rectal cancer. Nature. 2012;487(7407):330-337.
3. Kim DD, Eng C. The current state of targeted agents in rectal cancer. Int J Surg Oncol. 2012;2012:406830.
4. National Comprehensive Cancer Networks (NCCN). NCCN Clinical Practice Guidelines in Oncology Colon Cancer. Version 3. Fort Washington, PA: NCCN; 2013.
5. Wilhelm SM, Dumas J, Adnane L, etal. Regorafenib (BAY 73-4506): a new oral multikinase inhibitor of angiogenic, stromal and oncogenic receptor tyrosine kinases with potent preclinical antitumor activity. Int J Cancer. 2011;129(1):245-255.
6. Tsai JH, Lee WM. Tie2in tumor endothelial signaling and survival: implications for antiangiogenic therapy. Mol Cancer Res. 2009;7(3): 300-310.
7. Mross K, Frost A, Steinbild S, etal. A phase I dose-escalation study of regorafenib (BAY 73-4506), an inhibitor of oncogenic, angiogenic, and stromal kinases, in patients with advanced solid tumors. Clin Cancer Res. 2012;18(9):2658-2667.
8. Strumberg D, Scheulen ME, Schultheis B, etal. Regorafenib (BAY 73-4506) in advanced colorectal cancer: a phase I study. Br J Cancer. 2012;106(11):1722-1727.
9. Eisenhauer EA, Therasse P, Bogaerts J, etal. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer. 2009;45(2):228-247.
10. Bayer HealthCare. Patients with metastatic colorectal cancer treated with regorafenib or placebo after failure of standard therapy. In: ClinicalTrials. gov [website on the Internet]. Bethseda, MD: US National Library of Medicine; 2010 [updated July 18, 2013]. Available from: http://clinicaltrial.gov/show/NCT01103323. NLM identifier: NCT01103323. Accessed November 1, 2011.
11. Grothey A, Van Cutsem E, Sobrero A, etal; CORRECT Study Group. Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase 3 trial. Lancet. 2013;381(9863):303-312.
12. Stivarga® (regorafenib) tablets, for oral use [prescribing information]. Wayne, NJ: Bayer HealthCare Pharmaceuticals Inc; 2013. Available from: http://labeling.bayerhealthcare.com/html/products/pi/Stivarga_PI.pdf. Accessed November 1, 2013.
13. Spruance SL, Reid JE, Grace M, Samore M. Hazard ratio in clinical trials. Antimicrob Agents Chemother. 2004;48(8):2787-2792.
14. Van Cutsem E, Grothey A, Sobrero A, etal. Phase III CORRECT trial of regorafenib in metastatic colorectal cancer (mCRC): overall survival update. Presented at the European Society of Medical Oncology 2012 Congress, September 28-October 2, 2012, Vienna, Austria. Abstract LBA18.
15. Ricotta R, Sartore-Bianchi A, Verrioli A, Vanzulli A, Siena S. Regorafenib for metastatic colorectal cancer. Lancet. 2013;381(9877):1537.
16. Bayer HealthCare Pharmaceuticals Inc. Clinical Study Report 14387 (CORRECT). Wayne, NJ: Bayer HealthCare Pharmaceuticals Inc; 2012: 1-179.
17. Grothey A, Van Cutsem E, Sobrero A, etal. Time course of regorafenib-associated adverse events in the phase III CORRECT study. J Clin Oncol. 2012;30(Suppl 34):Abstract 467.
18. Porta C, Paglino C, Imarisio I, Bonomi L. Uncovering Pandora's vase: the growing problem of new toxicities from novel anticancer agents. The case of sorafenib and sunitinib. Clin Exp Med. 2007;7(4):127-134.
19. Lacouture ME, Wu S, Robert C, etal. Evolving strategies for the management of hand-foot skin reaction associated with the multitargeted kinase inhibitors sorafenib and sunitinib. Oncologist. 2008;13(9): 1001-1011.
20. Wood LS, Lemont H, Jatoi A, etal. Practical considerations in the management of hand-foot skin reaction caused by multikinase inhibitors. Community Oncol. 2010;7(1):23-29.
21. Ren Z, Zhu K, Kang H, etal. A randomized controlled phase II study of the prophylactic effect of urea-based cream on the hand-foot skin reaction associated with sorafenib in advanced hepatocellular carcinoma. J Clin Oncol. 2012;30(Suppl):Abstract 4008.
22. Bellmunt J, Eisen T, Fishman M, Quinn D. Experience with sorafenib and adverse event management. Crit Rev Oncol Hematol. 2011;78(1): 24-32.
23. Izzedine H, Ederhy S, Goldwasser F, etal. Management of hypertension in angiogenesis inhibitor-treated patients. Ann Oncol. 2009;20(5): 807-815.
24. Chobanian AV, Bakris GL, Black HR, etal; National Heart, Lung, and Blood Institute Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure; National High Blood Pressure Education Program Coordinating Committee. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report. JAMA. 2003;289(19):2560-2572.
25. Maitland ML, Bakris GL, Black HR, etal; Cardiovascular Toxicities Panel, Convened by the Angiogenesis Task Force of the National Cancer Institute Investigational Drug Steering Committee. Initial assessment, surveillance, and management of blood pressure in patients receiving vascular endothelial growth factor signaling pathway inhibitors. J Natl Cancer Inst. 2010;102(9):596-604.
26. Kollmannsberger C, Soulieres D, Wong R, Scalera A, Gaspo R, Bjarnason G. Sunitinib therapy for metastatic renal cell carcinoma: recommendations for management of side effects. Can Urol Assoc J. 2007;1(Suppl 2):S41-S54.
27. van Geel RM, Beijnen JH, Schellens JH. Concise drug review: pazopanib and axitinib. Oncologist. 2012;17(8):1081-1089.
28. Stein A, Voigt W, Jordan K. Chemotherapy-induced diarrhea: pathophysiology, frequency and guideline-based management. Ther Adv Med Oncol. 2010;2(1):51-63.
29. Benson AB 3rd, Ajani JA, Catalano RB, etal. Recommended guidelines for the treatment of cancer treatment-induced diarrhea. J Clin Oncol. 2004;22(14):2918-2926.
30. Campos MP, Hassan BJ, Riechelmann R, Del Gigilo A. Cancer-related fatigue: a practical review. Ann Oncol. 2011;22(6):1273-1279.
31. Schwandt A, Wood LS, Rini B, Dreicer R. Management of side effects associated with sunitinib therapy for patients with renal cell carcinoma. Onco Targets Ther. 2009;2:51-61.
32. Wood LS. Managing the side effects of sorafenib and sunitinib. Community Oncol. 2006;3:558-562.
33. Nexavar® (sorafenib) tablets, oral [prescribing information]. Wayne, NJ: Bayer HealthCare Pharmaceuticals Inc; 2010. Available from: http://www.accessdata.fda.gov/drugsatfda_docs/label/2010/021923s008s009lbl.pdf. Accessed November 1, 2013.
34. Sutent® (sunitinib malate) capsules, oral [prescribing information]. New York, NY: Pfizer Inc; 2011. Available from: http://www.accessdata.fda.gov/drugsatfda_docs/label/2011/021938s13s17s18lbl.pdf. Accessed November 1, 2013.
35. Argiles G, Troiani T, Rivera F, et al. First-line treatment with regorafenib in combination with mFOLFOX6 for metastatic colorectal cancer: a single-arm, open-label phase II clinical trial. Presented at the European Society of Medical Oncology 2013 Congress, September 27-October 1, 2013, Amsterdam, the Netherlands. Abstract 2367.
36. UNC Lineberger Comprehensive Cancer Center. Regorafenib+FOLFIRI Versus Placebo+FOLFIRI as 2nd Line Tx in Metastatic Colorectal Cancer. In: ClinicalTrials. gov [website on the Internet]. Bethseda, MD: US National Library of Medicine; 2011 [updated August 20, 2013]. Available from: http://clinicaltrial.gov/show/NCT01298570. NLM identifier: NCT01298570. Accessed November 1, 2011.
37. Bayer HealthCare. Regorafenib in subjects with metastatic colorectal cancer (CRC) who have progressed after standard therapy (CONSIGN). In: ClinicalTrials. gov [website on the Internet]. Bethseda, MD: US National Library of Medicine; 2012 [updated October 23, 2013]. Available from: http://clinicaltrial.gov/show/NCT01538680. NLM identifier: NCT01538680. Accessed November 1, 2011.